Use this url to cite publication: https://hdl.handle.net/20.500.12512/98602
Options
cfDNA amount and mutation profile analysis for gastric cancer patients / Greta Streleckiene, Michael Forster, Juozas Kupcinskas, Limas Kupcinskas, Jurgita Skieceviciene
Type of publication
Recenzuojamos išplėstinės tezės / Peer-reviewed extended theses (T1d)
Author(s)
Forster, Michael | Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Schleswig-Holstein, Kiel, Germany |
Title
cfDNA amount and mutation profile analysis for gastric cancer patients / Greta Streleckiene, Michael Forster, Juozas Kupcinskas, Limas Kupcinskas, Jurgita Skieceviciene
Publisher (trusted)
Council of LSMU Doctoral Students |
Date Issued
Date Issued |
---|
2019-04-08 |
Extent
p. 50-51.
Is part of
Health for all: Science and innovation week 2019 : International doctoral and resident students conference: Science for health : abstract book : Kaunas, Lithuania, 8-12 April, 2019 / Edited by Elvinas Monstavičius, Alvita Vilkevičiūtė. Kaunas : Council of LSMU Doctoral Students, 2019.
Version
Originalus / Original
Series/Report no.
Experimental medicine.
Field of Science
Abstract
Introduction Cell-free DNA (cfDNA) is released into the bloodstream in various ways including at the death of cells or by active secretion. It was shown that cfDNA could be a powerful disease state and relapse monitoring analyte. New minimally invasive diagnostic procedures are in demand because standard diagnostics are not able to analyze the cancer mutation profile changes over the course of treatment. However, there is a lack of comparative studies conducted in gastric cancer (GC) comparing tumor tissue DNA and cfDNA mutation profiles. Aim The aim of a study was to compare tumor tissue DNA and cfDNA mutation profiles and evaluate correlation of cfDNA amount and TNM stage for GC patients. Methods The study was approved by the Kaunas regional biomedical research ethics committee (No. Nr. BE-2-10). GC tissue and blood were collected from 30 patients who were recruited at the Department of Gastroenterology, Lithuanian University of Health Sciences Hospital. Quantification of plasma cfDNA was performed using Agilent TapeStation HS D5000 ScreenTape. Genomic DNA (gDNA) of tumor tissue and cfDNA were analyzed for mutations in cancer-related genes using xGen Pan-Cancer Panel (IDT) consisting of 7816 xGen Lockdown Probes for enrichment of 127 significantly cancer-related genes. Libraries were pair-end sequenced on an Illumina NextSeq 500. Results Overall, 16 patients had mutations detected in GC related genes and further analyzed for cfDNA mutation profile. Most frequently mutated genes in our study were TP53, BRCA2, NOTCH1, CHECK2, ERBB4, and KRAS. Yield of cfDNA is significantly increased for GC patients compared to controls and generally correlated with GC TNM stage and metastatic status. Conclusions Our results demonstrate that cfDNA reflects mutation profile in GC tissue DNA and yield of cfDNA correlates with TNM and metastatic status therefore may enable cfDNA analysis for monitoring of the metastatic burden or relapse risk in GC patients.
Type of document
type::text::conference output::conference proceedings::conference paper
ISSN (of the container)
2669-0314
Other Identifier(s)
(LSMU ALMA)990000980770107106
Coverage Spatial
Lietuva / Lithuania (LT)
Language
Anglų / English (en)